drugset / Trial / NCT03616795
Study of LY3154207 in Healthy Participants
NaSingle-groupOpen-labelBasic science
Summary
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3154207. This means that a radioactive substance C14 will be incorporated into the study drug, to investigate the study drug and its breakdown products, to find out how much of these pass from blood into urine, feces and expired air. The study will last about 4 weeks. Screening is required within 28 days prior to the start of the study and follow up is required approximately 7 days after discharge.
Timeline
- Start
- 2018-08-09
- Primary completion
- 2018-11-05
- Completion
- 2018-11-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mevidalen | Small molecule | 25 mg | Oral |
| Subject | Mevidalen | Small molecule | 200 mg | Oral |
| Subject | [14C]-LY3154207 | Unknown | 25 mg | Oral |
| Subject | [14C]-LY3154207 | Unknown | 200 mg | Oral |
Indications
No indication recorded.